20 out of 26 panelists vote to either ease restrictions or eliminate them entirely on...

|By:, SA News Editor

20 out of 26 panelists vote to either ease restrictions or eliminate them entirely on GlaxoSmithKline's (GSK) diabetes treatment Avandia after a two-day meeting at which FDA officials considered the results of a Duke University study which reportedly supports GSK's contention that heart worries surrounding the drug may be overblown.